Sep 29, 2022
CLS-Therapeutics’ project entering the Final at Hangzhou Innovation & Entrepreneurship Competition.

NEW YORK, NY /  September 28, 2022 / CLS Therapeutics, an oncology-focused gene therapy company that utilizes Extracellular DNA and NETs as novel anticacer therapeutic targets, announces that its project entered the final of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.

A presentation named “Anticancer Gene Therapy Platform Addressing A Novel Target to Treat Patients” is showcasing CLS Therapeutics’ data for the use of AAV-DNase (CLS-014) drug candidate  to treat the most hard-to-treat, therapy-resistant tumors. Today, CLS Therapeutics revolutionizes cancer therapy, since the proposed target was shown to play a primary role in the failure of existing anticancer therapies. The Company uses smart chimeric AAV technology for the delivery of the DNase I transgene to the liver, after which, hepatocytes start to produce a recombinant human DNase enzyme that destroys this cell-free DNA within tumor tissue.

The data will be presented by Dr. Tetz, MD, PhD., Chief Executive Officer of CLS Therapeutics. 

Sep 09, 2020

NEW YORK, NY /  September, 2020 / CLS Therapeutics, a preclinical-stage anticancer gene therapy platform company developing novel medicines to bring the curative power of cell-free DNA destruction to patients with tumors, presented preclinical data at the annual meeting of the American Society of Clinical Oncology (ASCO).

Sep 22, 2022

NEW YORK, NY /  September 22, 2022 / CLS Therapeutics,  cancer gene therapy company utilizing a novel therapeutic target, announces that its project  been selected as one of the semi-finalists of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.

Sep 18, 2019

NEW YORK, NY / ACCESSWIRE / September 18, 2019 / CLS Therapeutics, a privately held oncology-focused gene therapy company developing a platform technology based on the identification of a novel therapeutic target that can be utilized for many cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CLS-014 for the treatment of pancreatic cancer.h.